Recommendation not to start new patients on Tredaptive (ER niacin/laropiprant, MSD) in light of results of HPS2-THRIVE cardiovascular outcomes study

MSD would like to inform healthcare professionals that the HPS2-THRIVE study of TredaptiveTM did not meet its primary endpoint of reduction of major vascular events which included the combination of coronary deaths, non-fatal heart attacks, strokes or revascularisations. In addition, there was a statistically significant increase in the incidence of some types of non-fatal serious adverse events in the group that received TredaptiveTM and statin compared to the group that received statin alone. Given the current understanding of these new data and until additional analyses can be completed, physicians are advised not to start new patients on TredaptiveTM. It is not necessary at this time to stop TredaptiveTM in patients who are currently using the therapy. Healthcare professionals will be updated when new information becomes available.
Healthcare professional
Published:

Dear Healthcare Professional Letters

12 Dec 2019

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP), a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.hpp.moh.gov.sg and follow the procedures below to access the MOH Alert system.

Step 1: Select your profession under 'For Healthcare Professionals’.

Step 2: Click on 'Restricted Content' and log in via SingPass.

Step 3: Click on the MOH Alert icon under ‘Applications’.

Step 4: Click on the Drug Alert tab to view the DHCPLs.